{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"TOP","nct_id":"NCT04695925","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=top-nct04695925. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"TOP","arms":[{"description":"Osimertinib, 80mg, QD, p.o. until disease progression","label":"osimertinib monotherapy","type":"ACTIVE_COMPARATOR"},{"description":"Osimertinib, 80mg, QD, p.o. Pemetrexed 500 mg/m2 and carboplatin area under curve 5 intravenously every 3 weeks for four cycles, followed by maintenance pemetrexed.","label":"combination of osimertinib and chemotherapy","type":"EXPERIMENTAL"}],"collaborators":["Cancer Hospital of Guangxi Medical University","First People's Hospital of Foshan","Henan Cancer Hospital"],"completion_date":{"date":"2027-12-30","type":"ESTIMATED"},"conditions":["Non-small Cell Carcinoma","EGFR Gene Mutation"],"enrollment":{"count":294,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Osimertinib","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"}],"last_update":"2025-10-15","lead_sponsor":"Li Zhang, MD","official_title":"A Phase III, Multicentre, Randomized Controlled Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib, Carboplatin and Pemetrexed for Untreated Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations(TOP)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-11-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"progression free survival","timeFrame":"assessed up to 36 months"}],"references":[{"citation":"Zhou T, Zhou H, Gao F, Feng W, Jiang W, Huang L, Zhao F, Chen L, Ji M, Zhu J, Fang Y, Chen P, Wang P, Wu J, Zhuang L, Liu X, Deng M, Weng G, Li J, Yang C, Zhao H, Yang Y, Zhang L. Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. JAMA. 2026 Aug 10. doi: 10.1001/jama.2026.10599. Online ahead of print.","pmid":"42574006","type":"DERIVED"}],"start_date":{"date":"2021-03-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations","url":"https://clinicaltrials.gov/study/NCT04695925"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/top-nct04695925"}